Susan Abu-Absi, Ph.D. is a strategic operations executive with over 20 years of experience in product development and supply in the biopharmaceutical industry. She joined Be Bio in March 2025 as Chief Operating Officer, responsible for driving all operational aspects of the business to unleash the power of engineered B cell medicines as therapeutics for patients with serious diseases.
Prior to Be Bio, Susan was Chief Technology Officer at 2seventy bio where she led the Technical Development, Supply & Quality organization. Her team provided deep execution capabilities in autologous cell therapy manufacturing resulting in the launch of Abecma and the translation of four novel therapies with complex layered technologies into the clinic.
Prior to 2seventy bio, Susan led technical development & operations at bluebird bio, a pioneer in ex vivo gene therapies, where she played an integral role in the approvals of Zynteglo and Skysona.
Prior to joining bluebird, Susan held leadership roles in the Global Product Development and Supply organization at Bristol Myers Squibb. She started her career in the Process Sciences organization at Bayer Healthcare.
Susan earned a Ph.D. in Chemical Engineering from the University of Minnesota, where she conducted research in the laboratory of Professor Wei-Shou Hu as a National Science Foundation Fellow, and a B.S. in Chemical Engineering, Summa Cum Laude with Honors, from the University of Toledo.
